InsidersTradesSigma
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Discover the full record of transactions filed by Snyder Mark Howard. Director active across 1 company, notably Halozyme Therapeutics, INC.. Aggregated, 6 disclosures have been logged. Activity tracked since 3 January 2023. The latest transaction was disclosed on 23 February 2025 (Levée d'options). Regulator: SEC (Form 4). All data is free.
6 of 6 declarations